Halozyme Upsizes Convertible Offering to $1.3B, Sets 27.5% Conversion Premium
HALO sits 79% above its 52-week low of $61.225.
Summary
Halozyme priced its convertible senior notes offering at $1.3 billion, up from the $1.05 billion proposed two days ago, with a 1.50% coupon and a conversion premium of 27.5% above the September 17 closing price of $109.68. The notes are due 2033. The company also entered capped call transactions with a cap price of $208.39, representing a 90% premium, to reduce potential dilution. Net proceeds of approximately $1.275 billion will be used in part to repurchase $151.7 million of 2027 notes and $220.0 million of 2028 notes, with the remainder for general corporate purposes. The upsized deal and favorable terms suggest strong institutional demand, though the offering adds leverage and potential future dilution. The transaction is expected to close on September 22, 2026.
At the time of this announcement, HALO was trading at $109.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $61.23 to $111.15. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.